Exploring genomics and prognosis in gastrointestinal cancers
Explore the Correlation of Genomics and Prognosis in Alimentary Tract Cancers
This study is trying to see how genetic changes in patients with gastrointestinal cancers can help doctors understand their condition better and predict their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Health Research Institutes, Taiwan Academic / other |
| Locations | 2 sites (Tainan and 1 other locations) |
| Trial ID | NCT05767697 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect clinical specimens from patients with alimentary tract cancers, including various types of GI cancers. The investigators will perform extensive DNA and RNA analyses to identify genetic alterations and develop a comprehensive database of somatic mutations. The study will also investigate the correlation between these genetic changes and clinical, radiological, and pathological variables, utilizing advanced sequencing techniques. By understanding these relationships, the study seeks to enhance prognostic assessments for patients with GI cancers.
Who should consider this trial
Good fit: Ideal candidates include adults aged 20 and older with histologically confirmed GI cancers such as pancreatic, esophageal, gastric, liver, cholangiocarcinoma, or colorectal cancer.
Not a fit: Patients who are unable to cooperate with blood sampling or do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools for patients with gastrointestinal cancers based on their genomic profiles.
How similar studies have performed: Other studies have shown success in utilizing genomic profiling to improve prognostic outcomes in cancer, indicating that this approach is promising and not entirely novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able to sign the informed consent * Age \>= 20 * Histology proved pancreatic cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, cholangiocarcinoma, colorectal cancer * Agree to provide tumor/normal tissue including but not limited to surgical specimen, biopsy, cytology specimen, bile, urine or stool * Agree to receive blood sampling 20ml at first time and 10ml during each follow-up (total sampling amount no more than 30ml per month) Exclusion Criteria: * Cannot cooperate with blood sampling
Where this trial is running
Tainan and 1 other locations
- National Cheng-Kung University Hospital — Tainan, Taiwan (Recruiting)
- National Institute of Cancer Research — Tainan, Taiwan (Recruiting)
Study contacts
- Principal investigator: Li-Tzong Chen, MD PhD — National Health Research Institutes, Taiwan
- Study coordinator: Yung-Yeh Su, MD
- Email: yysu@nhri.edu.tw
- Phone: +886-6-7000123
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.